Table 4 The frequency of grade 1–2 and grade 3–4 fluoropyrimidines-related adverse events in patients with TYMS genotypes that predict decreased TS expression (2R/2R, 2R/3RC, and 3RC/3RC genotypes).
Adverse events | TYMS genotypes that predict decreased TS expression (N = 71) | |||||
|---|---|---|---|---|---|---|
2R/2R (N = 31) | 2R/3RC (N = 31) | 3RC/3RC (N = 9) | ||||
G 1–2 | G 3–4 | G 1–2 | G 3–4 | G 1–2 | G 3–4 | |
Hematological | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
Neutropenia | 11 (35) | 1 (3) | 9 (29) | 1 (3) | 1 (11) | 2 (22) |
Anemia | 8 (26) | 0 (0) | 6 (19) | 0 (0) | 2 (22) | 0 (0) |
Thrombocytopenia | 3 (10) | 0 (0) | 3 (10) | 0 (0) | 0 (0) | 0 (0) |
Neutropenic fever | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Non-hematological | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
Mucositis | 2 (6) | 3 (10) | 1 (3) | 0 (0) | 1 (11) | 0 (0) |
Nausea | 13 (42) | 2 (6) | 9 (29) | 0 (0) | 1 (11) | 0 (0) |
Vomiting | 2 (6) | 1 (3) | 2 (6) | 0 (0) | 1 (11) | 0 (0) |
Diarrhea | 4 (13) | 6 (19) | 2 (6) | 3 (10) | 1 (11) | 2 (22) |
Neurotoxicity | 0 (0) | 2 (6) | 3 (10) | 2 (6) | 0 (0) | 0 (0) |
Skin toxicity | 1 (3) | 3 (10) | 0 (0) | 4 (13) | 0 (0) | 1 (11) |
Fatigue | 17 (54) | 2 (6) | 8 (26) | 3 (10) | 2 (22) | 0 (0) |
Vasospasm | 0 (0) | 1 (3) | 0 (0) | 1 (3) | 0 (0) | 2 (22) |
